# Clinical Trials Data ERBB2 - Document 45

# A Feasibility Study for Women Receiving Anthracycline Chemotherapy With or Without Radiation for HER2-neu Positive Invasive Ductal Carcinoma

## Clinical Trial: https://clinicaltrials.gov/study/NCT02156648

"eligibilityCriteria": "Inclusion Criteria:\n\n1. Stage I-III, HER2-neu positive invasive ductal carcinoma\n2. Scheduled to receive adjuvant/neo-adjuvant 5-Fluorouracil, Epirubicin, Cyclophosphamide and Docetaxel (FEC-D) chemotherapy\n3. Scheduled to receive adjuvant Trastuzumab\n4. ECOG Performance status 0-2\n5. Adequate baseline imaging on transthoracic echocardiography, and baseline cardiac ejection fraction of \u2265 55%. Additionally, breast cancer patients\u226545 years of age and scheduled to receive whole breast radiation therapy will receive two cardiac PET scans.\n\nExclusion Criteria:\n\n1. Prior anthracycline chemotherapy\n2. History of dilated cardiomyopathy, congestive heart failure, or coronary artery disease\n3. Life expectancy less than 15 months\n4. Pregnant or lactating women\n5. Use of beta receptor antagonists, calcium channel antagonists, angiotensin converting enzyme inhibitors, or angiotensin receptor inhibitors at baseline.\n6. Previous chest wall/breast or nodal radiation.",  
 "healthyVolunteers": false,  
 "sex": "FEMALE",  
 "minimumAge": "19 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a ERBB2 gene mutation be eligible for the clinical trial?

Answer:  
Yes, a patient with an ERBB2 gene mutation would likely be eligible for this clinical trial, given that ERBB2 is another name for the HER2 gene. The inclusion criteria specify the requirement of HER2-neu positive invasive ductal carcinoma, which would be consistent with a mutation or amplification in the ERBB2/HER2 gene. Therefore, if the patient meets the other inclusion criteria (such as the specific stage of cancer and treatment plan) and none of the exclusion criteria, they would be eligible for the clinical trial.